Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 67

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Cerebral amyloid angiopathy

Not yet recruiting

Study on the Safety and Effects of Acetylcysteine Amide for Patients Aged 12 and Over with Hereditary Cystatin C Amyloid Angiopathy

InvestigationalNo placebo
Countries:IcelandIceland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Acetylcysteine Amide
  • Sponsor:Arctic Therapeutics ehf.

Krabbe's disease

Not yet recruiting

Study on Gene Therapy with AAVrh10 for Infants with Krabbe Disease Undergoing Stem Cell Transplantation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Adeno-Associated Virus Serotype Rh10 Containing The Human Galc Gene
  • Sponsor:Forge Biologics Inc.

Parkinson's disease

Not yet recruiting

Safety Study of Afamelanotide for Patients with Early Parkinson's Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Afamelanotide
  • Sponsor:Clinuvel Europe Limited

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Neurodegenerative disorder

Not yet recruiting

Study on Neurodegenerative Diseases Using [18F]RO6958948 for Early Detection and Mapping in At-Risk Patients

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3',4'-D]Pyrrole
  • Sponsor:Vaestra Goetalandsregionen

Dementia Alzheimer's type

Not yet recruiting

Study on JNJ-64042056 for Preclinical Alzheimer's Disease in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Jnj-64042056
  • Sponsor:Janssen Cilag International

Autism spectrum disorder

Not yet recruiting

Study on the Effects of Intranasal Oxytocin on Social and Repetitive Behaviors in Youth with Autism Spectrum Disorder

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Oxytocin Synthetic
  • Sponsor:Oslo University Hospital HF

Hypoxic ischaemic encephalopathy neonatal

Not yet recruiting

Study on Sildenafil and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sildenafil
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuroblastoma

Not yet recruiting

Study on the Safety of 68Ga-SATO and Iodine (123I) Iobenguane in Children with Neuroblastoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Satoreotide Trizoxetan Gallium (Ga68)
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Anaesthesia

Not yet recruiting

Study of Propofol and Thiopental for anesthesia induction in newborns under 47 weeks postmenstrual age

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Propofol
  • Sponsor:Odense University Hospital

Neuroblastoma

Not yet recruiting

Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:University Of Cologne

Anti-myelin-associated glycoprotein associated polyneuropathy

Not yet recruiting

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.